India, April 21 -- XORTX Therapeutics Inc. (XRTX) announced that it has regained compliance with Nasdaq's continued listing requirements, a key step that allows the late-clinical-stage company to maintain its U.S. exchange listing and continue advancing its kidney-disease pipeline.
The company received formal confirmation from Nasdaq after its shares traded above the required US$1.00 minimum bid price for 10 consecutive trading days following a 1-for-5 reverse stock split implemented on April 6, 2026.
XORTX focuses on developing therapies that target aberrant purine metabolism and xanthine oxidase activity to reduce uric acid levels- a pathway implicated in gout, polycystic kidney disease, and acute kidney injury. The company currently ha...